GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (NAS:MOR) » Definitions » Shiller PE Ratio
中文

MorphoSys AG (MorphoSys AG) Shiller PE Ratio

: (As of Today)
View and export this data going back to 2018. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


MorphoSys AG Shiller PE Ratio Historical Data

The historical data trend for MorphoSys AG's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Take a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, MorphoSys AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MorphoSys AG Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Shiller PE Ratio falls into.



MorphoSys AG Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

MorphoSys AG's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, MorphoSys AG's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.393/123.6675*123.6675
=0.393

Current CPI (Dec. 2023) = 123.6675.

MorphoSys AG Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.014 99.543 0.017
201406 -0.007 99.543 -0.009
201409 -0.032 99.823 -0.040
201412 -0.012 99.543 -0.015
201503 0.419 99.717 0.520
201506 -0.048 100.417 -0.059
201509 -0.090 100.417 -0.111
201512 -0.142 99.717 -0.176
201603 -0.078 100.017 -0.096
201606 -0.126 100.717 -0.155
201609 -0.137 101.017 -0.168
201612 -0.282 101.217 -0.345
201703 -0.139 101.417 -0.169
201706 -0.157 102.117 -0.190
201709 -0.247 102.717 -0.297
201712 -0.148 102.617 -0.178
201803 -0.207 102.917 -0.249
201806 -0.222 104.017 -0.264
201809 0.277 104.718 0.327
201812 -0.392 104.217 -0.465
201903 -0.203 104.217 -0.241
201906 -0.054 105.718 -0.063
201909 -0.209 106.018 -0.244
201912 -0.442 105.818 -0.517
202003 1.688 105.718 1.975
202006 -0.457 106.618 -0.530
202009 -0.589 105.818 -0.688
202012 -0.164 105.518 -0.192
202103 -0.378 107.518 -0.435
202106 0.184 108.486 0.210
202109 -0.971 109.435 -1.097
202112 -3.153 110.384 -3.532
202203 -0.988 113.968 -1.072
202206 -1.818 115.760 -1.942
202209 -0.891 118.818 -0.927
202212 2.556 119.345 2.649
202303 -0.348 122.402 -0.352
202306 -0.585 123.140 -0.588
202309 -0.934 124.195 -0.930
202312 0.393 123.668 0.393

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MorphoSys AG  (NAS:MOR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


MorphoSys AG Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (MorphoSys AG) Business Description

Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.